Wu is the dialect of Shanghai where Austrianova recently presented and the home of some of the most exciting biotech’s in China. (Wu is the dialect imaging endpoints requested for the job). Is it possible we are reviewing our imaging experts because our buyers partners require a shanghainese clinical trial imaging specialist to review our data?
Might be a valid reason to renew our ageeement with imaging endpoints.
Shanghai is where Gunzberg presented in September of last year at an investor event at Zhang Jiang Free Trade Zone and Innovation Centre near Shanghai.
All things point to China.
There’s something happening in the buyout or partnership zone isn’t there?
Does anyone think the reason there’s no wcb or CRO and a review of our imaging company is because Pharmacyte knows we’ll be bought out after the ind and don’t need them so best way to preserve cash? Just a thought.
Kw is in his seventies. Crabtree is older. Do these guys really want to go through years of trials or are they ready to cash in their millions of shares?
News 
Market Data 
Discover 
AI
